Cargando…
Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation
Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 (QSOX1) acting as a cellular pro-oxidant, specifically in the context of sorafenib treatment of HCC. QSOX1...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024711/ https://www.ncbi.nlm.nih.gov/pubmed/33770521 http://dx.doi.org/10.1016/j.redox.2021.101942 |
_version_ | 1783675367118077952 |
---|---|
author | Sun, Jialei Zhou, Chenhao Zhao, Yue Zhang, Xiaofei Chen, Wanyong Zhou, Qiang Hu, Bo Gao, Dongmei Raatz, Lisa Wang, Zhefang Nelson, Peter J. Jiang, Yuchao Ren, Ning Bruns, Christiane J. Zhou, Haijun |
author_facet | Sun, Jialei Zhou, Chenhao Zhao, Yue Zhang, Xiaofei Chen, Wanyong Zhou, Qiang Hu, Bo Gao, Dongmei Raatz, Lisa Wang, Zhefang Nelson, Peter J. Jiang, Yuchao Ren, Ning Bruns, Christiane J. Zhou, Haijun |
author_sort | Sun, Jialei |
collection | PubMed |
description | Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 (QSOX1) acting as a cellular pro-oxidant, specifically in the context of sorafenib treatment of HCC. QSOX1 disrupts redox homoeostasis and sensitizes HCC cells to oxidative stress by inhibiting activation of the master antioxidant transcription factor NRF2. A negative correlation between QSOX1 and NRF2 expression was validated in tumor tissues from 151 HCC patients. Mechanistically, QSOX1 restrains EGF-induced EGFR activation by promoting ubiquitination-mediated degradation of EGFR and accelerating its intracellular endosomal trafficking, leading to suppression of NRF2 activity. Additionally, QSOX1 potentiates sorafenib-induced ferroptosis by suppressing NRF2 in vitro and in vivo. In conclusion, the data presented identify QSOX1 as a novel candidate target for sorafenib-based combination therapeutic strategies in HCC or other EGFR-dependent tumor types. |
format | Online Article Text |
id | pubmed-8024711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-80247112021-04-13 Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation Sun, Jialei Zhou, Chenhao Zhao, Yue Zhang, Xiaofei Chen, Wanyong Zhou, Qiang Hu, Bo Gao, Dongmei Raatz, Lisa Wang, Zhefang Nelson, Peter J. Jiang, Yuchao Ren, Ning Bruns, Christiane J. Zhou, Haijun Redox Biol Research Paper Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 (QSOX1) acting as a cellular pro-oxidant, specifically in the context of sorafenib treatment of HCC. QSOX1 disrupts redox homoeostasis and sensitizes HCC cells to oxidative stress by inhibiting activation of the master antioxidant transcription factor NRF2. A negative correlation between QSOX1 and NRF2 expression was validated in tumor tissues from 151 HCC patients. Mechanistically, QSOX1 restrains EGF-induced EGFR activation by promoting ubiquitination-mediated degradation of EGFR and accelerating its intracellular endosomal trafficking, leading to suppression of NRF2 activity. Additionally, QSOX1 potentiates sorafenib-induced ferroptosis by suppressing NRF2 in vitro and in vivo. In conclusion, the data presented identify QSOX1 as a novel candidate target for sorafenib-based combination therapeutic strategies in HCC or other EGFR-dependent tumor types. Elsevier 2021-03-13 /pmc/articles/PMC8024711/ /pubmed/33770521 http://dx.doi.org/10.1016/j.redox.2021.101942 Text en © 2021 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Sun, Jialei Zhou, Chenhao Zhao, Yue Zhang, Xiaofei Chen, Wanyong Zhou, Qiang Hu, Bo Gao, Dongmei Raatz, Lisa Wang, Zhefang Nelson, Peter J. Jiang, Yuchao Ren, Ning Bruns, Christiane J. Zhou, Haijun Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation |
title | Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation |
title_full | Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation |
title_fullStr | Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation |
title_full_unstemmed | Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation |
title_short | Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation |
title_sort | quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving egfr endosomal trafficking and inhibiting nrf2 activation |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024711/ https://www.ncbi.nlm.nih.gov/pubmed/33770521 http://dx.doi.org/10.1016/j.redox.2021.101942 |
work_keys_str_mv | AT sunjialei quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT zhouchenhao quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT zhaoyue quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT zhangxiaofei quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT chenwanyong quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT zhouqiang quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT hubo quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT gaodongmei quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT raatzlisa quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT wangzhefang quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT nelsonpeterj quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT jiangyuchao quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT renning quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT brunschristianej quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation AT zhouhaijun quiescinsulfhydryloxidase1promotessorafenibinducedferroptosisinhepatocellularcarcinomabydrivingegfrendosomaltraffickingandinhibitingnrf2activation |